Evidence map›Paper›PMID 36709147›Full record

Observational studyZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].

H F Zhao, Y F Yang, B C Liu, W M Li, N Xu, X L Liu, Q Jiang, H B Dang, L X Liang, Yanli Zhang and 1 more

Open access · greenAbstract readObservational StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. [Advances in basic and clinical research of flumatinib].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

H F ZhaoDepartment of Hematology, Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Y F YangDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
B C LiuInstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
W M LiDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
N XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
X L LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Q JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Blood System Diseases, Beijing 100044, China.
H B DangThe First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China.
L X LiangDepartment of Hematology, Sanmenxia Central Hospital, Sanmenxia 472000, China.
Yanli ZhangDepartment of Hematology, Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Y P SongDepartment of Hematology, Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Southern Medical University · CNZhengzhou University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHenan Cancer Hospital · CNNanyang Medical College · CNUnion Hospital · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveTyrosine Kinase InhibitorsAgedAged, 80 and overEast Asian PeopleFemaleHumansImatinib MesylateInfant, NewbornMaleMiddle AgedProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeImatinib MesylateProtein Kinase InhibitorsTyrosine Kinase InhibitorsDeprescriptionsImatinibLeukemia, myeloid, chronicSecond-generation tyrosine kinase inhibitorsTreatment free remission

Identifiers

PMID36709147
PMCPMC9593009
OpenAlexW4318450544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.